- Home
- PCVX vs BIO Comparison
PCVX vs BIO Comparison
Compare PCVX & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCVX
- BIO
- Stock Information
- Founded
- PCVX 2013
- BIO 1952
- Country
- PCVX United States
- BIO United States
- Employees
- PCVX N/A
- BIO N/A
- Industry
- PCVX Biotechnology: Pharmaceutical Preparations
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- PCVX Health Care
- BIO Industrials
- Exchange
- PCVX Nasdaq
- BIO Nasdaq
- Market Cap
- PCVX 12.5B
- BIO 8.7B
- IPO Year
- PCVX 2020
- BIO N/A
- Fundamental
- Price
- PCVX $115.18
- BIO $329.99
- Analyst Decision
- PCVX Strong Buy
- BIO Buy
- Analyst Count
- PCVX 7
- BIO 4
- Target Price
- PCVX $147.50
- BIO $369.00
- AVG Volume (30 Days)
- PCVX 1.5M
- BIO 221.5K
- Earning Date
- PCVX 11-04-2024
- BIO 10-24-2024
- Dividend Yield
- PCVX N/A
- BIO N/A
- EPS Growth
- PCVX N/A
- BIO N/A
- EPS
- PCVX N/A
- BIO N/A
- Revenue
- PCVX N/A
- BIO $2,562,604,000.00
- Revenue This Year
- PCVX N/A
- BIO N/A
- Revenue Next Year
- PCVX N/A
- BIO $4.49
- P/E Ratio
- PCVX N/A
- BIO N/A
- Revenue Growth
- PCVX N/A
- BIO N/A
- 52 Week Low
- PCVX $44.20
- BIO $261.59
- 52 Week High
- PCVX $121.06
- BIO $366.30
- Technical
- Relative Strength Index (RSI)
- PCVX 73.46
- BIO 52.15
- Support Level
- PCVX $113.56
- BIO $311.04
- Resistance Level
- PCVX $121.06
- BIO $347.70
- Average True Range (ATR)
- PCVX 5.15
- BIO 9.84
- MACD
- PCVX 0.30
- BIO 0.58
- Stochastic Oscillator
- PCVX 56.27
- BIO 51.69
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.